Sign in to view content

Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY

Sunir J. Garg, MD, FACS, FASRS

Video
Published 2022

Related

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022

Category: AMD-Non-Neovascular

See more